ERBB2 and breast carcinoma: Kadcyla® (ado trastuzumab emtansine, T-DM1, anti-HER2-MCC-DM1) shows encouraging efficacy and safety in the treatment of HER2-positive breast cancer.19,20 Furthermore, replacing vc-MMAE with MCC-DM1 may help to overcome resistance.